Company intelligence / Profile preview

Guangdong Longfu Medicine

Zhongshan, Guangdong, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

The company has an NDA/approved drug (vidarabine for herpes zoster) and is the exclusive provider in China for "brain protein hydrolysate (II)" for injection for cerebral conditions. Its adenosine monophosphate for injection is the first approved generic in China and has significant market advantage. There is also one preclinical program.

Therapeutic areas: EndocrinologyInfectious DiseasesGastroenterologyPulmonologyCardiovascularOncologyNeurology
Modalities: Small moleculeChemical drugs
Industry: Biotech

Beyond the preview

Go deeper on Guangdong Longfu Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangdong Longfu Medicine.

Explore the full profile